| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | -184 | -184 |
| Proceeds from cirm grant | 2,520 | 2,520 |
| Proceeds from issuance of common stock related to atm, net of commissions | - | 534 |
| Proceeds from issuance of common stock-A2025ATMAgreement | 670 | - |
| Payment of issuance costs | 2,469 | 2,457 |
| Proceeds from issuance of common stock-Common Stock Purchase Agreement | 0 | - |
| Net cash provided by financing activities | 721 | 597 |
| Net decrease in cash, cash equivalents, and restricted cash | -36,032 | -26,710 |
| Cash and cash equivalents at beginning of period | 51,815 | - |
| Cash and cash equivalents at end of period | 15,783 | - |
Senti Biosciences, Inc. (SNTI)
Senti Biosciences, Inc. (SNTI)